Parenteral

INJECTA™ parenteral grade lipid excipients enable improved solubilization of injectable active pharmaceutical ingredients (APIs).  INJECTA lipid excipients undergo secondary sterile filtration and aseptic processing in state-of-the-art facilities to ensure products are of the highest quality.  The entire INJECTA product line is tested for pyrogens, microbial contaminants, elemental impurities, and particulate matter by validated testing protocols. 

Overview

The majority of new chemical entities (NCEs) being considered for therapeutic applications are BCS (Biopharmaceutics Classification System) Class II, Class III, or Class IV, indicating that these potential API’s will exhibit solubility and/or permeability challenges. Functional lipids are one of the most widely employed excipient classes for overcoming reduced bioavailability due to both solubility and permeability challenges. Many API’s which are insoluble in aqueous media can be dissolved in functional lipids improving their solubility by means of generating an oil in water emulsion carrier system for the API. Additionally, functional lipids can overcome certain permeability issues associated with delivering API's.

Related Applications

Oral   topical & transdermal   suppositories   ophthalmic

法律免责声明

CAPTEX^® 和 CAPMUL^® 是 ABITEC Corporation 的注册商标。本网站提供的所有信息和陈述在发布时均被认为准确。但是，ABITEC Corporation 及其附属公司对（包括但不限于）顾客或任何第三方因处理产品而产生的任何相关结果概不作任何声明或保证。所有信息和声明仅面向拥有相关技能和专门知识的人员，并不免除顾客或用户在使用产品前确认针对某一具体用途的信息和声明之合适性的义务。遵守相关法律法规以及所有专利或第三方的其他知识产权完全是顾客或用户的义务。ABITEC Corporation 明确声明，对于本网站上的任何信息和/或本网站所述或所宣传之任何产品，我们不作有关准确性、时效性、完整性及/或特定用途适销性或适合性的任何明示或暗示的声明或保证，包括不作有关是否侵犯任何专利、版权或第三方其他权利的保证。我们保留修改产品规格和产品之指定属性的权利，恕不另行通知。